Gene Expression Classifier for Eczema and Psoriasis Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing psoriasis and eczema often fail to accurately differentiate between the two conditions, leading to inappropriate therapy and suboptimal treatment outcomes, as they are influenced by high inter-individual variability and lack of validated classifiers.
Innovation Solution
A method involving the determination of specific marker expression levels, particularly using combinations of CCL27 and NOS2, or other pairs of markers from a list of 15 genes, to diagnose and differentiate between psoriasis and eczema, employing mRNA or protein expression data and a classifier algorithm for accurate assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical and histological methods are used to diagnose psoriasis and eczema, then the diagnostic process is simple and accessible, but the differentiation accuracy is insufficient leading to misdiagnosis
Solution Approach 1:
The patent replaces manual clinical and histological examination methods with an automated gene expression analysis system. The classifier algorithm processes mRNA expression data from skin biopsies to objectively differentiate psoriasis from eczema, substituting subjective clinical assessment with quantitative molecular diagnostics.
Solution Approach 2:
The patent introduces gene expression markers as intermediary indicators between the disease state and diagnostic conclusion. By measuring the expression levels of specific genes in skin tissue, the system creates a molecular bridge that provides more accurate disease differentiation than direct clinical observation alone.
2Measurement precision
If gene expression analysis with multiple markers is performed, then the diagnostic accuracy is improved, but the complexity of the diagnostic system increases
Solution Approach 1:
The patent extracts and focuses on a specific subset of gene expression markers that are most discriminatory for psoriasis versus eczema. Rather than analyzing all possible genes, the classifier identifies and measures only the relevant markers, reducing the complexity of analysis while maintaining high diagnostic accuracy.
Solution Approach 2:
The patent changes the diagnostic parameters from clinical observations to molecular expression levels. By measuring mRNA expression quantities of specific genes and feeding these quantitative parameters into the classifier, the system achieves more precise differentiation than qualitative clinical assessment.
3Reliability
If conventional therapy is applied without accurate diagnosis, then treatment can be initiated quickly, but inappropriate therapy leads to adverse reactions and suboptimal outcomes
Solution Approach 1:
The patent performs preliminary molecular characterization of the disease through gene expression analysis before initiating treatment. By determining the specific disease type (psoriasis or eczema) through classifier analysis of skin biopsy markers, the system ensures that the correct therapy is selected in advance, preventing inappropriate treatment and adverse reactions.
Data Source
AI summary
The present invention relates to a method of diagnosing eczema and/or psoriasis, wherein said method differentiates between eczema and psoriasis, and comprises determining the expression of at least two markers in a sample taken from an individual, wherein said at least two markers are selected from CCL27, NOS2, IL36G, KLK13, SOST, NPTX1, PLA2G4D, GDA, IL36A, TGM1, CLEC4G, IL13, TCN1, TMPRSS11D and RHCG, provided that said at least two markers consist of or comprise (a) CCL27 and NOS2; (b) CCL27 and KLK13; (c) IL36G and KLK13; (d) CCL27 and IL36G; (e) NOS2 and IL36G; (f) NOS2 and KLK13; (g) SOST; or (h) NPTX1; and assessing on the basis of the expression of said at least two markers whether the individual is afflicted with eczema and/or psoriasis.